Lytix Biopharma announced today the appointment of Dr. Andrew Saunders as its Chief Medical Officer (CMO), effective of January 19th, 2015. In his new role, Dr. Saunders will assume responsibility for all medical aspects of the company’s projects.
Prior to joining Lytix Biopharma, Dr. Saunders both founded and acted as Managing Director of Linden Oncology Limited, a consultancy providing strategic and clinical development haemato-oncology expertise to biotech and pharmaceutical companies globally.
Dr. Saunders obtained his medical degree from Trinity College Dublin, Rep. of Ireland in 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, U.K. He has worked in haemato-oncology since 1992, in clinical practice and the pharmaceutical and biotech industry. He has extensive experience in all aspects and phases of heamato-oncology drug development and has held positions as Clinical Research Physician at Eli-Lilly & company and Global Clinical Science Leader for Rituximab at Hoffman-La Roche.
Dr. Saunders commented “I am very much looking forward to joining Lytix Biopharma as Chief Medical Officer at such a critical time in the clinical development phase of the oncology drug candidate LTX-315.”
- Our recent progress and further anticipated advancement of the drug candidate LTX-315 has made the creation of the Chief Medical Officer position a corporate priority. We believe that Dr. Saunders is the perfect candidate to help us successfully moving forwards. His wealth of expertise in oncology will play a key role in the development of our valuable clinical assets, commented Unni Hjelmaas, CEO in Lytix Biopharma.